| Literature DB >> 24386416 |
Ze Zheng1, Chao Zhang1, Jianhua Yan2, Yanping Ruan2, Xiaoyi Zhao2, Xingting San3, Yilei Mao3, Qinghua Sun4, Kezhong Zhang5, Zhongjie Fan2.
Abstract
BACKGROUND: A number of case-control patient studies have been conducted to investigate the association between diabetes mellitus (DM) and hepatocellular carcinoma (HCC). Despite some controversial reports, it has been suggested that DM is associated with HCC. The previous studies on this subject vary in the selection of populations, sample sizes, methodology, and analysis results. Therefore, it is necessary to further delineate the involvement of DM, together with other related risk factors, in HCC with large sample size and strict analysis methodology.Entities:
Mesh:
Year: 2013 PMID: 24386416 PMCID: PMC3873428 DOI: 10.1371/journal.pone.0084776
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of Risk Factors and Demographics of the HCC and Controls Groups.
| Variable | Controls (n=716) | HCC (n=852) | χ2 | p | ||
|---|---|---|---|---|---|---|
| Frequency | Percent | Frequency | Percent | |||
| Male | 221 | 30.9 | 603 | 70.8 | 248.5 | <0.001 |
| Cirrhosis | 15 | 2.1 | 271 | 31.8 | 230.3 | <0.001 |
| HBsAg | 34 | 4.7 | 362 | 42.5 | 293.5 | <0.001 |
| Anti-HCV | 5 | 0.7 | 37 | 4.3 | 19.8 | <0.001 |
| Portal hypertension | 8 | 1.1 | 39 | 4.6 | 16.0 | <0.001 |
| Diabetes | 30 | 4.2 | 90 | 10.6 | 22.4 | <0.001 |
| Gallstone | 118 | 16.5 | 93 | 10.9 | 10.4 | 0.001 |
| Fatty liver | 29 | 4.1 | 17 | 2.0 | 5.8 | 0.016 |
| Hypertension | 118 | 16.5 | 167 | 19.6 | 2.6 | 0.110 |
HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
Comparison of Blood Risk Factors between the HCC and Controls Groups.
| Variable | Controls (Mean ±SD/ Median Q1-Q3) | HCC (Mean ±SD/ Median Q1-Q3) | t | p |
|---|---|---|---|---|
| Age (year) | 48.9 ± 13.1 | 57.5 ± 11.9 | -13.45* | <0.001 |
| ALT (IU/L) | 17.0 (12.0, 25.0) | 29.0 (18.0, 52.0) | -7.76* | <0.001 |
| AST (IU/L) | 20.0 (17.0, 24.0) | 32.0 (22.0, 48.5) | -11.01* | <0.001 |
| GGT (IU/L) | 23.0 (15.0, 41.0) | 51.0 (26.0, 98.0) | -6.95* | <0.001 |
| ALP (IU/L) | 61.0 (49.0, 81.0) | 82.0 (63.0, 108) | -5.85 | <0.001 |
| LDH (IU/L) | 162.1 ± 68.1 | 194.0 ± 93.7 | -7.68* | <0.001 |
| ChE (U/mL) | 7.2 ± 1.6 | 6.0 ± 1.9 | 13.1* | <0.001 |
| Glucose (mM) | 4.9 ± 0.8 | 5.4 ± 1.6 | -8.22* | <0.001 |
| TBA (µmol/L) | 3.8 (2.3, 6.3) | 6.5 (3.9, 12.8) | -7.29* | <0.001 |
| BU (µmol/L) | 12.7 (10.0,16.5) | 14.0 (10.4, 19.1) | -4.34* | <0.001 |
| BC (µmol/L) | 3.8 (3.0, 5.2) | 4.7 (3.5, 6.8) | -4.13* | <0.001 |
| TG (mmol/L) | 1.3 ± 0.9 | 1.2 ± 0.8 | 1.56* | 0.120 |
* Unequal variances; # Median and Quartile; Q1: the first quartile; Q3: the third quartile;
SD, standard deviation of the mean.HCC, Hepatocellular Carcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, glutamyltransferase; BU, total bilirubin; BC, direct bilirubin; ALP, alkaline phosphatase; TBA, total bile acid; LDH, lactate dehydrogenase;ChE, cholinesterase; TG, triglyceride;
Odds Ratios for Individual Effects of Predictors (Unadjusted Model) on HCC.
| Variables | OR (95% CI) | p |
|---|---|---|
| Male | 5.42 (4.37-6.74) | <0.001 |
| Age | 1.06 (1.05-1.07) | <0.001 |
| HBsAg | 14.80 (10.20-21.50) | <0.001 |
| Anti-HCV | 6.46 (2.52-16.51) | <0.001 |
| ALT | 1.02 (1.01-1.02) | <0.001 |
| AST | 1.05 (1.04-1.06) | <0.001 |
| GGT | 1.00 (1.00-1.01) | <0.001 |
| ALP | 1.00 (1.00-1.01) | <0.001 |
| LDH | 1.01 (1.01-1.01) | <0.001 |
| ChE | 0.69 (0.65-0.73) | <0.001 |
| Glucose | 1.51 (1.34-1.68) | <0.001 |
| TBA | 1.06 (1.04-1.08) | <0.001 |
| BU | 1.01 (1.01-1.02) | <0.001 |
| BC | 1.02 (1.01-1.03) | 0.003 |
| TG | 0.88 (0.75-1.03) | 0.110 |
| Tch | 0.79 (0.69-0.89) | <0.001 |
| HDL | 0.34 (0.23-0.52) | <0.001 |
| LDL | 0.81 (0.70-0.95) | 0.008 |
| APOA1 | 0.29 (0.17-0.48) | <0.001 |
| APOB | 0.59 (0.33-1.06) | 0.076 |
| LP(a) | 0.99 (0.98-0.99) | 0.011 |
| hs-CRP | 1.02 (1.00-1.03) | 0.015 |
| Cirrhosis | 21.8 (12.8-37.1) | <0.001 |
| DM | 2.70 (1.76-4.14) | <0.001 |
| Portal hypertension | 4.25 (1.97-9.14) | <0.001 |
| Gallstone | 0.62 (0.46-0.83) | 0.001 |
| Fatty liver | 0.48 (0.26-0.89) | 0.019 |
| Hypertension | 1.24 (0.95-1.60) | 0.110 |
Odds Ratio from Stepwise Logistic Regression Model for HCC.
| Variable | OR (95% CI) | P |
|---|---|---|
| Male | 3.08 (2.36-4.02) | <0.001 |
| Age | 1.06 (1.05-1.07) | <0.001 |
| HBsAg+ | 14.05(9.29-21.26) | <0.001 |
| Anti-HCV | 4.61(1.60-13.19) | 0.004 |
| Diabetes | 2.35 (1.36-4.05) | 0.002 |
| Gallstone | 0.38 (0.25-0.56) | <0.001 |
| ChE | 0.78 (0.72-0.84) | <0.001 |
| ALP | 1.003 (1.001-1.005) | 0.001 |
Odds Ratio from Adjusted Model by Controlling Age and Gender on HCC for Diabetes Cases (n=120).
| Variable | Controls (n=30) | HCC (n=90) | OR (95% CI) | p | ||
|---|---|---|---|---|---|---|
| Frequency or Mean | Percentor SD | Frequency or Mean | Percent or SD | |||
| Age | 60.2 | 10.5 | 63.7 | 9.1 | 1.05 (1.00-1.11) | 0.053 |
| Male | 13 | 43.3 | 65 | 72.2 | 2.37 (0.95-5.94) | 0.066 |
| HBsAg | 1 | 3.3 | 26 | 28.9 | 12.77 (1.57-104.13) | 0.017 |